Behavioural screening of zebrafish using neuroactive traditional Chinese medicine prescriptions and biological targets

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wang, Ya Nan ^a   Hou, Yuan Yuan ^a   Sun, Ming Zhu ^a   Zhang, Chun Yang ^a   Bai, Gang ^a   Zhao, Xin ^a   Feng, Xi Zeng ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT;

ANIMAL; CHEMISTRY; CHINESE MEDICINE; CIRCADIAN RHYTHM; CLASSIFICATION; CLUSTER ANALYSIS; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LARVA; MALE; MASS SPECTROMETRY; PHYSIOLOGY; PROCEDURES; TIME; ZEBRA FISH;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCADIAN RHYTHM; CLUSTER ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; FEMALE; LARVA; MALE; MASS SPECTROMETRY; MEDICINE, CHINESE TRADITIONAL; TIME FACTORS; ZEBRAFISH;

EID: 84902436395     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05311     Document Type: Article

References (60)

1. Belmaker, R. H. & Agam, G. Major depresssive disorder. N. Engl. J. Med. 358, 55-68 (2008).
2. Richelson, E. Pharmacology of antidepressants. Mayo Clin. Proc. 76, 511-527 (2001). (Pubitemid 32423135)
3. Perrine, S. A. et al. Ketamine reverses stress-induced depression-like behaviour and increased GABA levels in the anterior cingulate: An 11.7 T 1H-MRS study in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 51, 9-15 (2013).
4. Bauer, M., Tharmanathan, P., Volz, H. P., Moeller, H. J. & Freemantle, N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry. Clin. Neurosci. 259, 172-185 (2009).
5. Licinio, J. & Wong, M. L. Depression, antidepressants and suicidality: a critical appraisal. Nat. Rev. Drug Discov. 4, 165-171 (2005). (Pubitemid 40277496)
6. Halbreich, U. Major depression is not a diagnosis, it is a departure point to differential diagnosis-clinical and hormonal considerations: (a commentary and elaboration on Antonejevic's paper). Psychoneuroendocrinology. 31, 16-22 (2006). (Pubitemid 41668889)
7. Blais, R. K. & Renshaw, K. D. The association of biological and psychological attributions for depression with social support seeking intentions in individuals with depressive symptoms. Behav Cogn Psychother. 40, 605-617 (2012).
8. Ong, K. S. & Keng, S. B. The biological, social and psychological relationship between depression and chronic pain. Cranio. 21, 286-294 (2003). (Pubitemid 38859704)
9. Wilson, M. P., Castillo, E. M., Batey, A. M., Sapyta, J. & Aronson, S. Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. Int. J. Psychiatr. Med. 40, 199-215 (2010).
10. Antunes, P. B. & Fleck, M. P. Clinical outcomes and quality of life in patients submitted to electroconvulsive therapy. J. ECT. 25, 182-185 (2009).
11. Wijeratne, C. & Sachdev, P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 42, 751-762 (2008).
12. Belmaker, R. H. The future of depression psychopharmacology. CNS Spectr. 13, 682-7 (2008).
13. Tokita, K., Yamaji, T. & Hashimoto, K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol., Biochem. Behav. 100, 688-704 (2012).
14. Racagni, G. & Popoli, M. The pharmacological properties of antidepressants. Int. Clin. Psychopharmacol. 25, 117-31 (2010).
15. Anderson, H. D., Pace, W. D., Libby, A. M.,West, D. R. & Valuck, R. J. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: A retrospective US claims study. Clin. Ther. 34, 113-123 (2012).
16. Rascati, K., Godley, P. & Pham, H. Evaluation of resources used to treat adverse events of selective serotonin reuptake inhibitor use. Manag Care Pharm. 7, 402-406 (2001).
17. Bull, S. A. et al.Discontinuing or switching selective serotoninreup take inhibitors. Ann. Pharmacother. 36, 578-584 (2002). (Pubitemid 34270268)
18. Taylor, D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr. Scand. 118, 434-442 (2008).
19. George, M. & Burns Ewald, M. Three percent hypertonic saline as a therapy in reversal of the cardio toxic effects induced by tricyclic antidepressants. Clin. Toxicol. 46, 368-368 (2008).
20. Acikalin, A. et al. QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am. J. Ther. 17, 30-33 (2010).
21. Scheid, V. Depression, constraint, and the liver: (Dis) assembling the treatment of emotion-related disorders in Chinese medicine. Cult Med Psychiatry. 37, 30-58 (2013).
22. Ng, S. M., Chan, C. L. W., Ho, D. Y. F., Wong, Y. & Ho, R. T. H. Stagnation as a distinct clinical syndrome: comparing ''Yu'' (stagnation) in traditional Chinese medicine with depression. BJSW. 36, 467-484 (2006). (Pubitemid 43658942)
23. Katon, W. J. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 13, 7-23 (2011).
24. Spijkerman, T. et al. Depression following myocardial infarction: first-ever versus on going and recurrent episodes. Gen. Hosp. Psychiatry. 27, 411-417 (2005). (Pubitemid 41566067)
25. Du, Y. H. & Li, G. P. Theoretical basis of regulating mind and relieving the depressed liver needling method for treatment of depression. CAM. 25, 143-6 (2005).
26. Li, X. H., Li, J. J., Liu, Y. Y. & Chen, J. X. Central neurobiological mechanism of liver depression and spleen deficiency syndrome based on chronic stress: a review. JCIM. 10, 1-6 (2012).
27. Bianchi, G. et al. Psychological status and depression in patients with liver irrhosis. Dig. Liver Dis. 37, 593-600 (2005). (Pubitemid 44382339)
28. Kim, S. H. et al. Antidepression effect of Chaihu-Shugan-San extract and its constituents in rat models of depression. Life Sci. 76, 1297-1306 (2005).
29. Wang, Y., Fan, R. & Huang, X. Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression. J. Ethnopharmacol. 141, 571-577 (2012).
30. Zhang, Y. J. et al. Ferulic acid-induced anti-depression and prokinetics similar to Chaihu-Shugan-San via polypharmacology. Brain Res. Bull. 86, 222-228 (2011).
31. Zhang, G. & Ruan, J. Treatment of mental depression due to liver-qi stagnancy with herbal decoction and by magnetic therapy at the acupoints-a report of 45 cases. J. Tradit. Chin. Med. 24, 20-1 (2004). (Pubitemid 41238357)
32. Niv, N. et al. The use of herbal medications and dietary supplements by people with mental illness. Community Ment Health J. 46, 563-569 (2010).
33. Sarris, J., Kavanagh, D. J. & Byrne, G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J. Psychiatr. Res. 44, 32-41 (2010).
34. Kou,M. J. & Chen, J. X. Integrated traditional and Western medicine for treatment of depression based on syndrome differentiation: a meta-analysis of randomized controlled trials based on the Hamilton depression scale. J. Tradit. Chin. Med. 32, 1-5 (2012).
35. Kishimoto, N., Shimizu, K. & Sawamoto, K. Neuronal regeneration in a zebrafish model of adult brain injury. Dis. Model. Mech. 5, 200-209 (2012).
36. Maximino, C., de Brito, T.M., de Mattos Dias, C. A. G., Gouveia, A. Jr. & Morato, S. Scototaxis as anxiety-like behaviour in fish. Nat. Protoc. 5, 209-216 (2010).
37. Norton, W. & Bally-Cuif, L. Adult zebrafish as a model organism for behavioural genetics. BMC Neurosci. 11, 90 (2010).
38. Allgood, O. E. Jr. et al. Estrogen prevents cardiac and vascular failure in the 'listless' zebrafish (Daniorerio) developmental model. Gen. Comp. Endocrinol. 189, 33-42 (2013).
39. Kokel, D. et al. Rapid behaviour-based identification of neuroactive small molecules in the zebrafish. Nat. Chem. Biol. 6, 231-237 (2010).
40. Cachat, J. et al. Measuring behavioural and endocrain responses to novelty stress in adult zebrafish. Nat. Protoc. 5, 1786-1799 (2010).
41. Egan, R. J. et al. Understanding behavioural and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res. 205, 38-44 (2009).
42. Sison, M. & Gerlai, R. Associative learning in zebrafish (Daniorerio) in the plus maze. Behav. Brain Res. 207, 99-104 (2010).
43. Padilla, S., Hunter, D. L., Padons, B., Frady, S. & MacPhail, R. C. Assessing locomotor activity in larval zebrafish: Influence of extrinsic and intrinsic variables. Neurotoxicol. Teratol. 33, 624-630 (2011).
44. Rihel, J. et al. Zebrafish behavioural profiling links drugs to biological targets and rest/wake regulation. Science. 327, 348-351 (2010).
45. Moret, C. & Briley, M. The importance of norepinephrine in depression. Neuropsychiatr. Dis. Treat. 7, 9-13 (2011).
46. Xu, S. F., Zhuang, L. X., Tang, C. Z. & Yang, J. J. Effects of acupuncture and embedding thread on central monoamine neurotransmitters in the depression model rat. CAM. 27, 435-437 (2007).
47. Hindmarch, I. Expanding the horizons of depression: beyond the monoamine hypothesis. Hum. Psychopharmacol. 16, 203-218 (2001). (Pubitemid 32421887)
48. Prins, J., Olivier, B. & Korte, S. M. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin. Investig. Drugs. 20, 1107-1130 (2011).
49. Shulman, K. I., Herrmann, N. & Walker, S. E. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 27, 789-797 (2013).
50. Delgado, P. L. Depression: The case for a monoamine deficiency. J. Clin. Psychiatry. 61, 7-11 (2000). (Pubitemid 30217405)
51. Slattery, D. A. & Cryan, J. F. The role of GABAB receptors in depression and antidepressant-related behavioural responses. Drug Dev. Res. 67, 477-494 (2006). (Pubitemid 44621638)
52. Slattery, D. A. & Cryan, J. F. The role of GABA(B) receptors in depression and antidepressant-related behavioural responses. Drug Dev. Res. 67, 477-494 (2006). (Pubitemid 44621638)
53. Cryan, J. F. & Slattery, D. A. GABA(B) receptors and depression: current status. Adv. Pharmacol. 58, 427-451 (2010).
54. Hashimoto, K. The role of glutamate on the action of antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 35, 1558-68 (2011).
55. Zarate, C. Jr. et al. Glutamatergic modulators: the future of treating mood disorder? Harv. Rev. Psychiatr. 18, 293-303 (2010).
56. Valentine, G. W. & Sanacora, G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol. 78, 431-9 (2009).
57. Pathak, L., Agrawal, Y. & Dhir, A. Natural polyphenols in the management of major depression. Expert Opin. Investig. Drugs. 22, 863-80 (2013).
58. Donato, F. et al. Hesperidin exerts antidepressant-like effects in acute and chronic treatments in mice: Possible role of I-arginine-NO-cGMP pathway and BDNF levels. Brain Res. Bull. 104, 19-26 (2014).
59. Lee, B., Shim, I., Lee, H. & Hahm, D. H. Effect of ginsenoside Re on depressionand anxiety-like behaviors and cognition memory deficit induced by repeated immobilization in rats. J. Microbiol. Biotechnol. 22, 708-20 (2012).
60. Yamada, N., Araki, H. & Yoshimura, H. Identification of antidepressant-like ingredients in ginseng root (Panax ginseng C. A. Meyer) using a menopausal depressive-like state in female mice: participation of 5-HT2A receptors. Psychopharmacology. 216, 589-599 (2011).